PCNA and cancer: A cell permeable peptide (R9-caPep) containing the L126-Y133 sequence of PCNA selectively blocks PCNA interactions in cancer cells and interferes with DNA synthesis and HR-mediated DSB repair, resulting in S-phase arrest, an accumulation of DNA damage, and an enhanced sensitivity to cisplatin [9].